December 20, 2021

Supply chain optimization in cell and gene therapies

Reading time: 3 minutes

The logistics branches of biopharma companies experience a major paradigm shift. The supply chains for conventional small molecule drug products and biologics involve the acquisition of raw materials, the manufacturing process of pharmaceutical goods, transporting them to pharmacies and provider inventories and finally distribution to the patient with subsequent reimbursement to a third-party payer.

With the introduction of cell and gene therapy products (CGT) like CAR T-cells therapies and allogeneic therapies to the healthcare market, this linear logistic concept for therapeutics was shattered in several aspects:

  • flow of material, information and financials
  • regulations around quality, handling and traceability of human cell products
  • diminishing separation between treatment clinical sites and biopharmaceutical companies
  • challenges for traditional distributors: modification of patient’s own cells for autologous cell therapies result in closed-loop supply chains
  • shift from keeping an inventory towards providing a just-in-time distribution chain supporting flexible deliveries with short filling times
  • strict clinical site schedule adherence to ensure meeting patient’s treatment timeline and expiration dates of gene therapy products
  • provider organizations are suppliers and customers, hence complex service contracts that involve regulating the handling of GMP materials
  • cell & gene therapies require use of emerging interorganizational digital platforms to orchestrate all stakeholders in real-time
Logistics for CAR t-cell therapy by Single Use Support

Cell and gene therapy – a rapidly expanding market

The ground-breaking approvals of Novartis’ Kymriah (tisagenlecleucel) and Kite Pharma’s Yescarta (axicabtagene ciloleucel) CAR T-cell therapies in 2017 paved the way for hundreds of potential innovative cell and gene therapies, that are in early to late-stage clinical trials right now. These developments are highly promising for medicine, life sciences, uncounted patients with life-threatening diseases and biopharmaceutical companies alike. This market growth is expected to further accelerate with a projected approval rate of 10-20 CGTs per year by 2025, as predicted by former FDA commissioner Scott Gottlieb.

However, the scale-up needed to successfully commercialize cell and gene therapies is highly challenging. The CGT production process requires a specialized environment to ensure high-quality personalized therapies that cannot be provided in traditional large volume manufacturing sites. Additionally, the supply chain management for CGTs will become increasingly complex to sustain their specific requirements.

Cell and Gene Therapy Supply chain challenges due to increasing complexity

For over one century, a mostly linear supply chain from the manufacturing site to patients was predominant. Cell and gene therapies require biotech companies to follow a different approach.

As an example for autologous cell therapies, the production of CAR T-cells begins in healthcare centers with harvesting blood cells from patients in a process termed apheresis. The blood cells must be frozen and transported to the therapy manufacturing site, oftentimes partnerships with contract manufacturing organizations (CMOs). Transport must occur under strictly cryogenic conditions, e. g. liquid nitrogen, within 50 hours, therefore a reliable cold chain must be in place.

After modification of the native T-cells into therapeutic CAR T-cells, the logistics for treatment of the patient have to be taken care of. This requires orchestration of all stakeholders:

  • the biopharma company’s manufacturing site to prepare the shipment
  • the delivering organization to organize the appropriate mode of transportation and cold chain
  • the healthcare center to receive the shipment, and prepare facilities and personnel
  • the patient to be ready to receive the treatment

Additionally, such personalized, advanced therapies are naturally patient centric and require a chain of identity and chain of custody as validation that they arrive at the right patient, as potential mix-ups are absolutely intolerable.

Any mistakes or transgressed lead times in supply chain management have the potential to cause tremendous financial loss and are probably devastating for patients.

CGT or CAR-T logistic solution "RoSS KSET" - Protect your cell & gene therapy (CGT) bags

Rise of smart packaging and technologies has started

A much needed approach to solving problems related to supply chain management is the development of smart packaging and related smart technologies. Ideally, smart packaging enters the picture in the very first steps of CGT production, e.g. during cell collection for CAR T therapy. It should be easy to use for personnel in the clinical setting, e.g. taking care of convenient labeling or tagging of vials and bags and allow for fast, controlled freezing to enter the cold chain. During the shipment, it should monitor, and transmit physical variables such as temperature, location tracking, orientation and shocks and send push notifications to stakeholders when exceeding certain predefined limits to allow rapid intervention. Moreover, it should reliably protect the contents from impacts, shear forces and tearing.

Innovative companies like Single Use Support take these growing requirements into consideration and work hard on the development of scalable supply chain solutions to overcome any emergent hurdles. The scalability of cell and gene therapy depends on innovative smart packaging companies.

Supply chain optimization in cell and gene therapies

Dr. Barbara M. Fischer

Process Consultant & Senior Sales Application Engineer

Barbara Fischer, Single Use Support


For any press related inquiries, please reach out to